Overall survival 3 years [clinicaltrials_resource:9cb0653c33f9467e0044d4ef965cd125]
Patients receive 1 of 3 preoperative chemoradiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Overall survival 3 years [clinicaltrials_resource:9cb0653c33f9467e0044d4ef965cd125]
Patients receive 1 of 3 preoperative chemoradiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
9cb0653c33f9467e0044d4ef965cd125
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9cb0653c33f9467e0044d4ef965cd125
measure [clinicaltrials_vocabulary:measure]
Overall survival
time frame [clinicaltrials_vocabulary:time-frame]
description
Patients receive 1 of 3 preope ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:9cb0653c33f9467e0044d4ef965cd125
title
Overall survival 3 years
@en
type
label
Overall survival 3 years [clinicaltrials_resource:9cb0653c33f9467e0044d4ef965cd125]
@en